Replimune reports Q2 net loss $83.1M; FDA accepts RP1 BLA resubmission with PDUFA April 10, 2026

Replimune Group, Inc.

2026-Q2 EPS reported -$1.85

Cash, equivalents and investments $323.6M at Sep 30, 2025, down from $483.8M at Mar 31, 2025.
R&D expenses $57.9M vs $43.4M YoY; S,G&A $26.4M vs $15.5M YoY.
Net loss $83.1M vs $53.1M in prior year quarter.
FDA accepted BLA resubmission for RP1 in advanced melanoma; PDUFA target action date April 10, 2026.
Phase 3 IGNYTE-3 trial enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.